Table 2. . Diagnosis outcomes.
| Patients (%) | |
|---|---|
| Initial diagnosis aided by ENB procedure | |
| Malignant tissue: | 36/71 (50.7) |
| – NSCLC: | 26/71 (36.6) |
| • Adenocarcinoma | 13/71 (18.3) |
| • Squamous carcinoma | 9/71 (12.7) |
| • Large cell/neuroendocrine tumor | 2/71 (2.8) |
| • Other NSCLC† | 2/71 (2.8) |
| – Small cell carcinoma | 2/71 (2.8) |
| – Sarcoma | 1/71 (1.4) |
| – Metastatic disease | 7/71 (9.9) |
| Nonmalignant tissue: | 35/71 (49.3) |
| – Inflammation | 24/71 (33.8) |
| – Infection | 6/71 (8.5) |
| – Benign‡ | 5/71 (7.0) |
| Final diagnosis after all follow-up§ | |
| Malignant | 52/84 (61.9) |
| Inflammation | 23/84 (27.4) |
| Infection | 6/84 (7.1) |
| Benign | 3/84 (3.6) |
†Other includes: NSCLC-not otherwise specified (n = 1) and sarcomatoid carcinoma (n = 1).
‡Includes four cases ultimately determined to be true negative (one read as atypical calls, two read as ‘no malignancy’, and one read as ‘benign alveolar tissue’) and one case ultimately determined to be false negative.
§Out of the 86 patients with ENB-aided biopsy attempted, follow-up was available in 84 patients.
ENB: Electromagnetic navigation bronchoscopy.